Tian Hui, Huang Dazhi, Li Tao, Huang Lihua, Zheng Xingguang, Tang Danxia, Zhang Lu, Wang Jian
School of Life Science and Technology, Mianyang Normal University Mianyang, China.
School of Pharmacy, Chengdu University of Traditional Chinese Medicine Chengdu, China.
Int J Clin Exp Med. 2015 Nov 15;8(11):20279-86. eCollection 2015.
Magnolia officinalix Rehd. et Wils is a kind of herb which is widely used for gastrointestinal tract mobility disorder in Asian countries. In this study, we investigated whether the total phenols of Magnolia officinalix Rehd. et Wils (TPM) treatment improves gastrointestinal tract dysmobility induced by intraperitoneal injection of atropine (5 mg/kg) in rats. Rats were randomly grouped into three units: TPM-pretreated/atropine-treated group, atropinetreated group and control group. TPM were administrated for 7 days. Gastric residual rate and intestinal transit were measured 20 min after atropine injected, and gastrointestinal hormones (including: gastrin (GAS), motilin (MTL), somatostatin (SS) and p substance (PS) levels in serum were also measured by ELISA kits. The number and distribution of interstitial cells of Cajal (ICCs) in stomach were detected by immunohistochemistry analysis, while c-kit and stem cell factor (SCF) expressions in stomach were also measured by western blotting. We found that TPM pretreatment significantly improved atropine-induced gastric residual rate increase, while had no significantly effects on intestinal transit; it also significantly normalized GAS, MTL and PS serum levels. Atropine-induced ICCs numbers decreased in both sinuses ventriculi and body of stomach, which is improved by TPM pretreatment. Western blotting results showed the expressions of c-kit and SCF were down-regulated after atropine injection, which can be reversed with TPM pretreatment. These results above indicates that TPM treatment can significantly protected atropine-induced gastric dysmoblility, which may owed to its regulation on c-kit/SCF signing pathway.
厚朴是一种在亚洲国家广泛用于治疗胃肠道运动障碍的草药。在本研究中,我们调查了厚朴总酚(TPM)治疗是否能改善腹腔注射阿托品(5mg/kg)诱导的大鼠胃肠道运动障碍。大鼠被随机分为三组:TPM预处理/阿托品治疗组、阿托品治疗组和对照组。TPM给药7天。在注射阿托品20分钟后测量胃残留率和肠传输率,并用ELISA试剂盒检测血清中的胃肠激素(包括:胃泌素(GAS)、胃动素(MTL)、生长抑素(SS)和P物质(PS)水平)。通过免疫组织化学分析检测胃中Cajal间质细胞(ICC)的数量和分布,同时通过蛋白质印迹法测量胃中c-kit和干细胞因子(SCF)的表达。我们发现,TPM预处理显著改善了阿托品诱导的胃残留率增加,而对肠传输率没有显著影响;它还显著使GAS、MTL和PS血清水平恢复正常。阿托品诱导的胃窦和胃体ICC数量减少,TPM预处理可改善这一情况。蛋白质印迹结果显示,注射阿托品后c-kit和SCF的表达下调,TPM预处理可使其逆转。上述结果表明,TPM治疗可显著保护阿托品诱导的胃运动障碍,这可能与其对c-kit/SCF信号通路的调节有关。